You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

group of patients
Recommend SHINGRIX

Recommend SHINGRIX(herpes zoster vaccine, recombinant, adjuvanted) to your patients 50 years of age and older at their next visit.1

patient profile 1

Meet Jennifer*

She feels healthy, but she’s still at risk.1,2

Who are the people in Jennifer’s life?

  • Her husband and 2 children in secondary school
  • The employees in her flower shop
  • Her running buddies

Lifestyle:

She eats healthily, walks every day, and runs a few times a week

Medical History:

No current medical issues

Interaction With HCP:

Diligent about annual health check ups, and is proactive in discussing lifestyle changes to help keep herself healthy

Recommendation Opportunity:

When scheduling a flu vaccination

*Not an actual patient

patient profile 2

Meet Sam*

He prioritises taking care of others over himself.

Who are the people in Luis’ life?

  • His wife, 3 children, and parents who live with him
  • The team at his software development company
  • His parents, who are not as healthy as they once were

Lifestyle:

He does not eat a healthy diet and is usually too busy to exercise

Medical History:

Type 2 diabetes

Interaction With HCP:

Reluctant about visiting the doctor and only goes a few times a year to review HbA1C levels

Recommendation Opportunity:

  • When in for patient review
  • When seeking a repeat prescription
  • When scheduling a flu vaccination

*Not an actual patient

patient profile 3

Meet 
Richard*

He is getting older, but shingles prevention is not top of mind.3

Who are the people in Richard’s life?

  • His wife and his daughter, who is a doctor
  • His students and faculty at the university where he works
  • His grandchildren whom he visits at least once a week

Lifestyle:

He doesn’t exercise enough and has become less mobile with age

Medical History:

Cardiovascular (CV) disease

Interaction With HCP:

Leans too much on daughter for medical advice

Recommendation Opportunity:

  • When in for medical review
  • When seeking a repeat prescription
  • When in for seasonal vaccinations

*Not an actual patient

patient profile 4

Meet Betty*

With so much to manage in relation to her health, she’s not thinking about shingles.3

Who are the people in Betty’s life?

  • Her 4 children and 8 grandchildren
  • Her close circle of friends nearby

Lifestyle:

She walks in the park when she can, and maintains a healthy diet to help manage her cholesterol

Medical History:

Gout, high cholesterol, macular degeneration, hypertension

Interaction With HCP:

Overwhelmed with seeing multiple specialists, she doesn’t always keep up with GP visits

Recommendation Opportunity:

  • When in for medical review
  • When seeking repeat prescription
  • When in for seasonal vaccinations

*Not an actual patient

More information on SHINGRIX

References

  1. Shingrix, Summary of Product Characteristics (SPC), available on https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed: March 2022
  2. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  3. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  4. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  5. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
  6. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90. 

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255. 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

SHINGRIX is owned by or licensed to the GSK group of companies. © 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-210006 | Date of Preparation: April 2022